Rarecells

About:

Rarecells Inc. is a healthcare company focused on the development and commercialization of non-invasive Early Cancer Detection tests.

Website: https://www.rarecells.com

Twitter/X: RarecellsFrance/

Top Investors: AA Sons, Globivest

Description:

Rarecells, Inc. is a healthcare company focused on the development and commercialization of non-invasive Early Cancer Detection tests. These tests are based on the ISET® platform technology that is able to extract from blood cancer cells from any type of cancer. Cancer cells extracted by ISET® are then diagnostically identified through immune-morpho molecular analyses combined with image analyses and AI. This approach is believed to be a significant advancement in the highly sensitive non-invasive detection of cancer’s signals providing a powerful tool for early cancer detection through the identification of the first circulating cancer cells.

Total Funding Amount:

$13M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Paris, Ile-de-France, France

Founded Date:

2010-01-01

Contact Email:

contact(AT)rarecells.com

Founders:

Patrizia Paterlini Brechot

Number of Employees:

11-50

Last Funding Date:

2021-12-09

IPO Status:

Private

Industries:

© 2025 bioDAO.ai